Research & Development
Tuberculosis: Page 2
How pathologists act as 'firefighters' during COVID-19
Especially in the early stages of the pandemic, there were numerous unknowns about how to proceed with autopsies because COVID-19 was an unknown disease. What type of infectious disease was it? Was it like tuberculosis, HIV, hepatitis C, or mad cow disease?
October 3, 2021
PerkinElmer to buy Oxford Immunotec Global
The acquisition will help PerkinElmer expand its infectious disease testing portfolio to include tuberculosis detection, giving it access to Oxford Immunotec's T-cell immunology technology for testing latent tuberculosis, it said.
January 6, 2021
Qiagen debuts solution for SARS-CoV-2 T-cell research
QuantiFeron SARS-CoV-2 ROU is a modular system based on the platform Qiagen developed for its QuantiFeron-TB Gold Plus test for latent tuberculosis.
December 6, 2020
Cepheid's tuberculosis test detects drug resistance
The company's Xpert Mycobacterium tuberculosis/extensively drug-resistant (MTB/XDR) test identifies tuberculosis that is resistant to first- and second-line drugs, particularly the disease's most complicated form -- XDR-TB -- the company said.
July 15, 2020
Qiagen TB blood test gets thumbs up in Nigeria
Nigeria is the first high-burden country to exclusively embrace interferon gamma release assays (IGRAs) for latent TB screening of at-risk individuals in tuberculosis control programs, Qiagen noted. The national guidelines are based on World Health Organization (WHO) recommendations for screening, and including IGRA tests will help avoid progression to active TB, Dr. Adebola Lawanson, national coordinator of the TB program at the Nigeria Federal Ministry of Health, said in a statement from the company.
February 20, 2020
Which eligible gene signatures make the grade for TB blood tests?
The review evaluated whole blood mRNA signatures that have been proposed for identifying the onset of TB. The authors used a patient-level pooled dataset of four studies that included 1,126 samples from 905 patients, with 183 samples from 127 cases of incipient tuberculosis, which is defined as the asymptomatic phase of disease. The dataset included cases from African countries -- South Africa, Ethiopia, and Gambia -- and the U.K.
January 19, 2020
Startup develops POC diagnostic for tuberculosis
The platform is initially intended for use in South Africa. Eventually, the technology could be applied to detect other organisms responsible for conditions in other geographies.
December 8, 2019
Qiagen TB blood test headed for wider global use
The GDF facilitates the procurement and supply of tuberculosis medicines, diagnostics, and lab supplies to public health organizations globally. Qiagen said in a statement that the GDF stamp of approval will open a new channel in countries where tuberculosis is common and where Qiagen has no direct commercial presence.
October 30, 2019
GNA Biosolutions secures $13.5M in new funding round
GNA said it plans to use the funds to advance the development of its point-of-care molecular diagnostic platform as well as help bring it to the clinic -- first in the European Union and then in the U.S. market. The platform can support the creation of simple, cost-effective molecular diagnostic tests and has already facilitated the production of more than 30 internal assays for hospital-acquired infections and tuberculosis, among other diseases, according to the firm.
August 4, 2019
NIH funds creation of granuloma lab model for TB and HIV
Texas Biomed has a two-year study grant to create a model for granulomas, which are masses of macrophages, lymphocytes, and other cells that form in response to an infection with Mycobacterium tuberculosis. In people infected with HIV and TB, HIV is present in granulomas. The interaction is complex, and animal models haven't been up to the task of evaluation, Texas Biomed said in a statement.
June 27, 2019
Page 2 of 2